

Continuing Education Program Opportunities for ASHP State Affiliates

ASHP Advantage, a division of ASHP, can partner with ASHP state affiliates to conduct continuing education programs in your state.

How it works: ASHP Advantage obtains an educational grant to develop a series of regional programs that can be conducted during ASHP affiliate meetings. The grant will be used to pay for the honorarium and travel expenses for a nationally-recognized pharmacist expert to present at an ASHP affiliate event (typically an annual meeting). If the program is conducted as one of the core meeting programs, ASHP Advantage will provide the handout and evaluation form in electronic format. The affiliate is responsible for scheduling and promoting the program, duplicating the handout, providing the AV, and administering the program onsite.

Funding: ASHP Advantage obtains an educational grant from a commercial supporter to plan and conduct the program. The grant covers the direct costs including development of the content and presentation materials as well as speaker travel and honorarium. All programs are planned and conducted by ASHP Advantage. The program will be planned and developed in accordance with the FDA's Guidelines for Industry-Sponsored Scientific and Educational Activities, ACCME Essential Areas and Standards for Commercial Support, and ACPE Guidelines.

CE: In most cases, ASHP serves as the provider of continuing education for the program. Participants will be directed to our online CE processing center to print statements of continuing education after the program. ASHP can also co-sponsor programs with affiliates, upon request.

Format: Programs are offered in a variety of formats (one to two hours in duration) so they can be tailored to fit the preferred schedule for affiliate events. Programs are designed to be highly interactive and feature opportunities for case discussions and other participative learning techniques.

Speakers: Programs are presented by nationally-recognized experts from various health systems across the United States.

Catering: If the program is conducted as part of the core educational schedule of an affiliate meeting, catering is not provided. Selected programs may be conducted as free-standing events or satellite programs and scheduled with other commercially-supported programs during approved times. A meal may be provided at these programs. If the program is conducted as a free-standing or satellite event, ASHP Advantage will promote the program directly to attendees and administer the program onsite.

Topics: Currently, ASHP Advantage is offering programming in four therapeutic areas (1) acute coronary syndrome, (2) venous thromboembolism, (3) meeting national performance measures related to antithrombotic therapy, and (4) tumor lysis syndrome. Detailed descriptions for each program are outlined below.

To schedule one of these programs at your meeting, please contact Kim Cackowski at kcackowski@ashpadvantage.com.

Title: Improving Outcomes of Anticoagulant Therapy in Patients with Non-ST-Elevation Acute Coronary Syndrome: 2008 Update

Duration: 1 hour

Description: This program will include an overview of the epidemiology, pathophysiology, and patient presentation of NSTEMI ACS and the pharmacology of anticoagulants. An update on evidence-based guidelines and new clinical data for the use of anticoagulant therapy in patients with NSTEMI ACS will be provided, using case studies to illustrate key concepts.

Title: Applying ACC/AHA Guidelines to Anticoagulant Therapy in the Management of Acute Coronary Syndrome

Duration: 1.5 hours

Description: This program will include an overview of the epidemiology, pathophysiology, and patient presentation of NSTEMI ACS and STEMI, and the pharmacology of anticoagulant agents. Case studies will be used to illustrate the application of ACC/AHA guidelines for the management of NSTEMI ACS and STEMI in clinical practice.

Title: A Case-Based Approach to Optimizing Anticoagulant Therapy in Acute Coronary Syndrome

Duration: 2.0 hours

Description: This program will include an overview of the epidemiology, pathophysiology, and patient presentation of NSTEMI ACS and STEMI, and the pharmacology of anticoagulants. Case studies will be used to illustrate the application of ACC/AHA guidelines for anticoagulant therapy in the management of NSTEMI ACS and STEMI, including patients who are obese, patients with severe renal impairment, and patients who develop HIT. The use of evidence-based performance measures to evaluate quality of care as part of quality initiatives to improve care in patients with ACS also will be addressed.

Title: Improving Quality of Antithrombotic Therapy through the Use of National Performance Measures

Duration: 1 hour

Description: Safe and effective antithrombotic therapy has been the focus of national quality initiatives that use evidence-based performance measures to evaluate and improve the quality of patient care. Reducing the likelihood of patient harm associated with the use of anticoagulant therapy has been established as a 2008 National Patient Safety Goal (NPSG) by the Joint Commission. The Joint Commission and the National Quality Forum have developed national consensus standards for the prevention and care of VTE. Health care providers need education and tools to evaluate and improve the quality of antithrombotic use in their institutions and meet the standards and goals

established by various national organizations. This presentation will focus on these quality initiatives and provide strategies for using performance measures to assess and improve quality of care and meet national standards and goals in the clinical practice setting.

Title: Providing Quality Antithrombotic Therapy: Meeting the Challenge of National Performance Measures

Duration: 1.5 hours

Description: This program will provide an historic perspective on the development of performance measures, describe the magnitude of the problem with antithrombotic therapy for patients with or at risk for VTE or with ACS, and outline performance measures for antithrombotic therapy in these patients that have been established by various national organizations. Possible strategies for improving performance and patient outcomes will be discussed.

Program Title: Anticoagulant Therapy Update: Improving Outcomes for Venous Thromboembolism

Duration: 1.0 hour

Description: This program is designed to provide pharmacists with an overview of the epidemiology, pathophysiology, risk factors, clinical presentation, and diagnosis of VTE as well as strategies for prevention and treatment. The pharmacology and monitoring requirements of agents will be reviewed. An update on evidence-based guidelines and new clinical data for the use of anticoagulant therapy in patients with or at risk for VTE will be provided. Participants will be engaged in an active learning process through the use of interactive questions that will illustrate key concepts covered in the program.

Title: Applying Evidence-Based Guidelines for Anticoagulant Therapy in the Prevention and Treatment of Venous Thromboembolism

Duration: 1.5 hours

Description: This interactive program will include an overview of the epidemiology, pathophysiology, clinical presentation, and diagnosis of VTE; risk factors for VTE; and interventions for prevention and treatment of VTE. The pharmacology and monitoring requirements of anticoagulants will be reviewed. Opportunities will be provided to discuss the assessment of risk for VTE and the application of the American College of Chest Physicians (ACCP) guidelines for the prevention and treatment of VTE in clinical practice.

Title: A Case-Based Approach to Preventing and Treating Venous Thromboembolism with Anticoagulant Agents

Duration: 2.0 hours

Description: This program will include an overview of the epidemiology, pathophysiology, clinical presentation, and diagnosis of VTE; risk factors for VTE; and interventions for prevention and treatment of VTE. The pharmacology and monitoring requirements of

anticoagulants will be reviewed. Challenging patient cases requiring VTE risk assessment, application of the American College of Chest Physicians (ACCP) guidelines, and selection of VTE prevention and treatment strategies in clinical practice will be presented.

Title: Prevention and Treatment of an Oncologic Emergency: Focus on Tumor Lysis Syndrome

Duration: 1.0, 1.5, or 2.0 hours

Description: Tumor Lysis Syndrome (TLS) is a group of metabolic abnormalities resulting from the spontaneous or treatment-related rapid break down of malignant tumor cells, is a serious and potentially life-threatening medical emergency. When TLS occurs, it is essential that the patient receive prompt medical attention in order to prevent the acute complications that can have severe repercussions including death of the patient. This program will help pharmacists appropriately identify patients who are at high risk of developing TLS. Monitoring and providing treatment options for patients who develop this medical emergency or those for whom prophylactic therapy is warranted will also be addressed. Case studies will be used to illustrate key concepts.